li001

Zongertinib: A Novel EGFR Inhibitor in Advanced Non-Small Cell Lung Cancer Treatment

Leave a Comment / Immunotherapy /

Zongertinib is a newly approved oral targeted therapy for patients with unresectable or metastatic HER2-mutated non-squamous non-small cell lung cancer (NSCLC) who have received prior treatment. Approved by the FDA in August 2025, it is the first oral option specifically for this patient group, marking a significant advance in targeted lung cancer therapy. Zongertinib works […]

Zongertinib: A Novel EGFR Inhibitor in Advanced Non-Small Cell Lung Cancer Treatment Read More »

Zusduri: Revolutionizing Bladder Cancer Treatment Through Targeted Local Delivery

Leave a Comment / Treatment /

Zusduri is the first FDA-approved targeted, non-surgical treatment for recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. It delivers mitomycin C directly into the bladder using RTGel® technology, which turns from liquid to gel at body temperature. This allows the drug to stay in contact with the bladder wall for hours, maximizing local effect while minimizing

Zusduri: Revolutionizing Bladder Cancer Treatment Through Targeted Local Delivery Read More »

Artificial Intelligence in Complex Liver Cancer Surgery: Precision Oncological Resection

Leave a Comment / Technology Innovation /

AI is transforming liver cancer surgery by improving precision, planning, and safety. It helps surgeons better understand the liver’s complex anatomy, allowing more accurate tumor removal while preserving healthy tissue. This leads to safer procedures and better overall outcomes for patients. Before surgery, AI converts CT and MRI scans into detailed 3D models, enabling “virtual

Artificial Intelligence in Complex Liver Cancer Surgery: Precision Oncological Resection Read More »